Latent Labs vs Nabla Bio (2026)
This is the sharpest pairing in the set. Both design antibodies from scratch against hard targets, both publish technical reports with their hit rates and the targets they missed, and both benchmark against the same competitor. The difference is how a buyer reaches the platform. Latent Labs runs it as a product: a browser platform and an API with a free daily quota for approved researchers and paid credits for larger campaigns, plus a Latent-Y agent that runs a whole design campaign from a written goal. Nabla Bio keeps JAM inside its own discovery collaborations rather than offering self serve access, and concentrates on the membrane protein class, with results reported target by target. Latent is the one when a team wants to run de novo antibody design itself, starting today on a free tier. Nabla is the one when the work is a partnership on a membrane target and the platform does the designing.
- A self serve platform and API, with a free daily quota and an agent that runs a full design campaign.
- Published reports across antibodies, nanobodies and macrocyclic peptides, including a ten donor immunogenicity panel.
- A fit for a research team that wants to design antibodies itself rather than hand off a target.
- De novo design delivered inside a discovery collaboration, concentrated on membrane proteins.
- Hit rates published target by target, including where the model produced no binder.
- Collaborations with three large pharmaceutical companies against the platform.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Latent Labs and Nabla Bio are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Latent Labs | Nabla Bio |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | Not recorded | 2021 |
| Headquarters | London, United Kingdom | Cambridge, Massachusetts, United States |
| Website | latentlabs.com | nabla.bio |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Latent Labs its top capability grade on AI Centrality. Set against Nabla Bio, Latent Labs grades higher on AI Safety and PHI Stewardship, HIPAA and BAA Posture and Commercial Transparency. Its thinnest published disclosure sits on Security Certifications and Trust Center and EHR and Interoperability Depth. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, October 2026
The AI Health Index awards Nabla Bio its top capability grade on AI Centrality and AI Governance and Bias Disclosure. Set against Latent Labs, Nabla Bio grades higher on AI Governance and Bias Disclosure. Its thinnest published disclosure sits on several axes, including AI Safety and PHI Stewardship, HIPAA and BAA Posture and Security Certifications and Trust Center. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, October 2026
Questions buyers ask
Should we choose Latent Labs or Nabla Bio?
On the axes where the AI Health Index separates them, Latent Labs grades higher on AI Safety and PHI Stewardship, HIPAA and BAA Posture and Commercial Transparency, and Nabla Bio grades higher on AI Governance and Bias Disclosure. Latent Labs leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Latent Labs and Nabla Bio differ most?
The widest separation the AI Health Index records between Latent Labs and Nabla Bio is on AI Safety and PHI Stewardship, where Latent Labs grades B and Nabla Bio grades D. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Latent Labs and Nabla Bio grade the same?
The AI Health Index grades Latent Labs and Nabla Bio the same on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Latent Labs and Nabla Bio not disclosed?
At the last review, at least one of Latent Labs and Nabla Bio published thin or absent detail on several axes, including AI Safety and PHI Stewardship, HIPAA and BAA Posture and Security Certifications and Trust Center. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Both records were reviewed in October 2026. Latent Labs publishes a free research tier and sells larger use through credits and partnerships; Nabla works through discovery collaborations and publishes no price. Both post technical reports rather than peer reviewed papers.
Ask both for design success rates with denominators on targets like yours, and how each reports and handles the designs that fail.